RecruitingPHASE1, PHASE2NCT06843408
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
Studying Chronic graft versus host disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Incyte Medical MonitorIncyte Corporation
- Intervention
- INCA034176(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2025 – 2027
Study locations (9)
- Peking University People'S Hospital, Beijing, China
- West China Hospital of Sichuan University, Chengdu, China
- The Second Affiliated Hospital, Army Medical University (Xinqiao Hospital), Chongoing, China
- Zhujiang Hospital of Southern Medical University, Guangzhou, China
- Nanfang Hospital of Southern Medical University, Guangzhou, China
- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Shanghai Children'S Medical Center, Shanghai, China
- Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China
- Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06843408 on ClinicalTrials.govOther trials for Chronic graft versus host disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07394608Paired Non-invasive VNS in Adolescent Cerebral Palsy RehabilitationIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT07124078A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)Incyte Corporation
- RECRUITINGEARLY PHASE1NCT07355868Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell TherapyRegend Therapeutics
- RECRUITINGNANCT06857929"Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition"IMDEA Food
- RECRUITINGPHASE1NCT07389044A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis BIntegerBio
- RECRUITINGNCT07127926Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHDM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT07138196A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host DiseaseQurient Co., Ltd.
- ACTIVE NOT RECRUITINGNCT07321080Central Sensitisation in Nociceptive and Neuropathic PainIRCCS Centro Neurolesi Bonino Pulejo